Near-infrared fluorescent probes for imaging of amyloid plaques in Alzheimer׳s disease

Acta Pharm Sin B. 2015 Jan;5(1):25-33. doi: 10.1016/j.apsb.2014.12.006. Epub 2015 Jan 2.

Abstract

One of the early pathological hallmarks of Alzheimer׳s disease (AD) is the deposition of amyloid-β (Aβ) plaques in the brain. There has been a tremendous interest in the development of Aβ plaques imaging probes for early diagnosis of AD in the past decades. Optical imaging, particularly near-infrared fluorescence (NIRF) imaging, has emerged as a safe, low cost, real-time, and widely available technique, providing an attractive approach for in vivo detection of Aβ plaques among many different imaging techniques. In this review, we provide a brief overview of the state-of-the-art development of NIRF Aβ probes and their in vitro and in vivo applications with special focus on design strategies and optical, binding, and brain-kinetic properties.

Keywords: AD, Alzheimer’s disease; APP, amyloid peptide precursor; Ach, acetylcholine; Alzheimer׳s disease; Amyloid-β plagues; Aβ, amyloid-β; BAP, BODIPY-based Ab imaging probe; BBB, blood-brain barrier; Blood-brain barrier; Cy, cyanine dyes; Fluorescence probe; ICG, indocyanine green dyes; MRI, magnetic resonance imaging; NIR, near-infrared; NIRF, near-infrared fluorescence; Near-infrared fluorescence; Optical imaging; PET, positron emission tomography; ROS, reactive oxygen species; SPECT, single photon emission computed tomography.

Publication types

  • Review